Dopamine receptor binding on identified striatonigral neurons.
Dopamine receptors have been divided into two families, known as D1 and D2, based on their ability to bind distinct ligands, and their use of separate post-synaptic transduction systems. Determining the specific cellular location for these dopamine receptors in the striatum is important to the design of drug treatments for disorders with suspected dopaminergic involvement such as Parkinson's disease. This study examined the binding of D1 and D2 antagonist ligands on identified striatonigral neurons using in vitro fluorescent techniques. The results indicate that striatonigral neurons express both pharmacological subfamilies of dopamine receptor binding sites.
Larson
E R
ER
Department of Neuroscience, Chicago Medical School, IL 60064.
Ariano
M A
MA
D000818:Animals; D001552:Benzazepines; D005456:Fluorescent Dyes; D008297:Male; D017072:Neostriatum / Q000166:cytology / Q000378:metabolism*; D009434:Neural Pathways / Q000166:cytology / Q000187:drug effects; D009474:Neurons / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000187:drug effects / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism*; D013050:Spectrometry, Fluorescence; D013134:Spiperone / Q000031:analogs & derivatives / Q000494:pharmacology; D013378:Substantia Nigra / Q000166:cytology / Q000378:metabolism*
D001552:Benzazepines; D005456:Fluorescent Dyes; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D013134:Spiperone; C043186:N-(4-aminophenethyl)spiroperidol